Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Thrice-Daily Premixed Human Insulin vs Basal-Bolus in T2DM
NCT06855615Phase 4Completed
- Sponsor
- Hospital Sultanah Aminah
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hospital Sultanah Aminah. Primary endpoint: Glycated Haemoglobin at 12 weeks. Started Oct 2020; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06855615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855615.